PNC-27 regulatory status
Current status of PNC-27 in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of PNC-27?
Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 22, 2026
- FDA and compounding
- Not an FDA approved drug and never submitted for FDA review. PNC-27 has not been nominated for the 503A bulks list and does not appear in any FDA compounding category, so licensed pharmacies cannot lawfully compound it. FDA issued a public warning in January 2017 telling cancer patients not to buy or use PNC-27 products after laboratory testing found bacterial contamination in a solution marketed for inhalation.
- WADA
- WADA prohibited
- Access path
- Not legally available for human use in the United States.
- No registered clinical trial is recruiting as of the last verified date.
- Products sold online are unapproved and FDA has specifically warned against them.
Full PNC-27 page: evidence, dosing in the literature, and sources
How has the status of PNC-27 changed over time?
No dated regulatory event has been recorded for PNC-27. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for PNC-27 and the source of each dated event.